All In Biotech

Drug Trial Radar · NCT04815148

MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid Arthritis

A Phase Ia/Ib Study to Evaluate the Safety, Tolerability and PK of MH004 Topical Cream in Healthy Adult Volunteers and to Investigate Its Efficacy and Safety Profile in Participants With Atopic Dermatitis or Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Mar 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

72

Planned (sponsor's estimate)

Start

Apr 1, 2021

Primary completion

Mar 31, 2022

Study completion Mar 31, 2022

Sponsor

Lead sponsor
Minghui Pharmaceutical Pty LtdIndustry
Sponsor type
Industry
First posted
Mar 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase Ia/Ib Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis and participants with Mild to Moderate Rheumatoid Arthritis.

Conditions

  • Atopic Dermatitis
  • Rheumatoid Arthritis

Interventions

  • MH004 Ia(0.1%)Drug

    Spread approx. 1 g of MH004 topical cream to the upper thigh skin.

  • MH004 Ia(0.3%)Drug

    Spread approx. 1 g of MH004 topical cream to the upper thigh skin.

  • MH004 Ia(1%)Drug

    Spread approx. 1 g of MH004 topical cream to the upper thigh skin.

  • MH004 Ia(3%)Drug

    Spread approx. 1 g of MH004 topical cream to the upper thigh skin.

  • MH004 Ib-1(0.1%)Drug

    Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.

  • MH004 Ib-1(0.3%)Drug

    Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.

  • MH004 Ib-1(1%)Drug

    Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.

  • MH004 Ib-2(0.3%)Drug

    Spread approx. 0.5 g of MH004 topical cream to the Target Joint.

  • MH004 Ib-2(1%)Drug

    Spread approx. 0.5 g of MH004 topical cream to the Target Joint.

  • MH004 Ib-2(3%)Drug

    Spread approx. 0.5 g of MH004 topical cream to the Target Joint.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the incidence and severity of Treatment-Emergent Adverse Events [Safety and Tolerability].Time frame: 1 year
  2. To determine the maximum tolerated dose (MTD) of MH004 topical cream.Time frame: 1 year
  3. To establish the recommended phase 2 dose (RP2D).Time frame: 1 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.